SEC (Securities and Exchange Commission) warns Lumenis over likely legal action
This article was originally published in Clinica
The US Securities and Exchange Commission (SEC) has sent Yokneam, Israel-based Lumenis a Wells Notice, indicating that it may be preparing civil proceedings against the laser therapy firm. The move comes as part of an investigation by the SEC's Boston district office into Lumenis's accounts. Lumenis will now have time to discuss the issues with the SEC before the latter decides what action to take.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.